Mass Drug Administration (MDA), defined by WHO as the administration of antimalarial treatment to all age groups of a defined population or every person living in a defined geographical area (except those for whom the medicine is contraindicated) at approximately the same time and often at repeated intervals, has been historically a key component of malaria control and elimination strategies. With the aim of facilitating the discussions at the Evidence Review Group (ERG) on MDA for malaria held in September 2018, this deep dive compiles the landscape of recent and ongoing research in antimalarial MDA and provides an overview of the projects’ main characteristics.